S&P Futures
5,845.50 -3.50 (-0.06%) Dow Futures
42,569.00 -36.00 (-0.08%) Nasdaq Futures
20,372.50 -7.75 (-0.04%) Russell 2000 Futures
2,229.00 -2.00 (-0.09%) Crude Oil
70.32 +0.13 (+0.19%) Gold
2,739.90 -9.00 (-0.33%)
Eledon Pharmaceuticals, Inc. (ELDN)
After hours:
| Previous Close | 3.4900 |
| Open | 3.5400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 3.4100 - 3.6200 |
| 52 Week Range | 1.0700 - 3.6500 |
| Volume | |
| Avg. Volume | 64,526 |
| Market Cap | 146.496M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | 7.70 |
| EPS (TTM) | 0.4600 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
GlobeNewswireEledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 8:35 a.m. ET. To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company’s website under Events. About El
- GlobeNewswire
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Enrollment Completed Four Months Ahead of ScheduleIRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has successfully completed enrollment for its Phase 2 BESTOW clinical trial, which is designed to assess the safety and efficacy of its investigational immunosuppression therapy tegoprubart for the prevention of organ rejection in patients undergoing kidney transplantation. The trial reached its target enrollment of 12
- GlobeNewswire
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment) enrolled in Phase 2 BESTOW trial Completed an oversubscribed $50 million private placement; Company expects sufficient liquidity through December 2025 IRVINE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported recent business highlights f
